The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 22, 2020

Filed:

Oct. 18, 2019
Applicants:

Fred Hutchinson Cancer Research Center, Seattle, WA (US);

Seattle Children's Hospital, Seattle, WA (US);

Inventors:

Michael C. Jensen, Bainbridge Island, WA (US);

Stanley R. Riddell, Sammamish, WA (US);

Michael Hudecek, Leipzig, DE;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/7151 (2013.01); C07K 16/2803 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/70 (2013.01);
Abstract

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.


Find Patent Forward Citations

Loading…